Tests on Pigs Show Promising Results for Quivax Vaccine
Photo: Screenshot | Communication and Media UAQ
By Ana Karina Vazquez | Newspaper of Queretaro
The Autonomous University of Querétaro (UAQ) and its research team have made significant progress in the development of the Quivax vaccine. In their semi-annual activity report, they announced the successful generation of antibodies in mice and pigs against the most concerning variants of Covid-19. Additionally, the allocated budget of 13 million pesos has been fully utilized.
The leader of the research project, Juan Joel Mosqueda Gualito, emphasized that current vaccines only protect against severe illness and death, not against infection. However, it has been observed that even after recovering from the infection, there are long-term health repercussions.
The researcher from the Faculty of Natural Sciences explained the need for continued research in developing new generation vaccines due to the emergence of new variants that current vaccines do not protect against. The current vaccines were approved for emergency use, and it is crucial to explore more effective options.
Tests conducted on pigs have shown promising results, with the development of antibodies that protect against all known variants of concern. Collaborating with the Center for Research and Advanced Studies (CUNVESTAV), the team administered an intranasal vaccine, which also demonstrated favorable outcomes.
The team will publish three academic manuscripts and three theses, including both bachelor’s and master’s theses. They have also obtained approval for a patent in the name of UAQ. The final report will be presented in November, and an external audit will ensure transparency and accountability in the use of resources. The rector highlighted that the investment of 13 million pesos is relatively small compared to the development of other vaccines, such as AstraZeneca, which required over two billion pesos.
Garcia Gasca, the rector, mentioned that eight vaccine projects were initiated in the country, but only one, the Patria vaccine, received support from the federal government, with an investment of over a billion pesos. While more support was expected, the achieved results demonstrate the country’s talent and the availability of necessary infrastructure for such projects.
Subscribe to our Newsletter and receive the most relevant news in your email
“With this generation of knowledge, surely the next pandemic will not catch us so unawares.”
The Autonomous University of Querétaro (UAQ) and its research team have made significant progress in the development of the Quivax vaccine. In their semi-annual activity report, they announced the successful generation of antibodies in mice and pigs against the most concerning variants of Covid-19. Additionally, the allocated budget of 13 million pesos has been fully utilized.
The leader of the research project, Juan Joel Mosqueda Gualito, emphasized that current vaccines only protect against severe illness and death, not against infection. However, it has been observed that even after recovering from the infection, there are long-term health repercussions.
The researcher from the Faculty of Natural Sciences explained the need for continued research in developing new generation vaccines due to the emergence of new variants that current vaccines do not protect against. The current vaccines were approved for emergency use, and it is crucial to explore more effective options.
Tests conducted on pigs have shown promising results, with the development of antibodies that protect against all known variants of concern. Collaborating with the Center for Research and Advanced Studies (CUNVESTAV), the team administered an intranasal vaccine, which also demonstrated favorable outcomes.
The team will publish three academic manuscripts and three theses, including both bachelor’s and master’s theses. They have also obtained approval for a patent in the name of UAQ. The final report will be presented in November, and an external audit will ensure transparency and accountability in the use of resources. The rector highlighted that the investment of 13 million pesos is relatively small compared to the development of other vaccines, such as AstraZeneca, which required over two billion pesos.
Garcia Gasca, the rector, mentioned that eight vaccine projects were initiated in the country, but only one, the Patria vaccine, received support from the federal government, with an investment of over a billion pesos. While more support was expected, the achieved results demonstrate the country’s talent and the availability of necessary infrastructure for such projects.
Subscribe to our Newsletter and receive the most relevant news in your email
“With this generation of knowledge, surely the next pandemic will not catch us so unawares.”
Further News
The Autonomous University of Querétaro (UAQ) and its research team have made significant progress in developing the Quivax vaccine. In their semi-annual activity report, they announced the successful generation of antibodies in mice and pigs against the most concerning variants of Covid-19. The allocated budget of 13 million pesos has been fully utilized. The leader of the research project emphasized the need for continued research in developing new generation vaccines to protect against emerging variants. Tests conducted on pigs have shown promising results, with the development of antibodies that protect against all known variants of concern. The team will publish academic manuscripts and theses, and has obtained approval for a patent. The final report will be presented in November, with an external audit to ensure transparency in resource use. The rector of UAQ mentioned that despite limited government support, the progress achieved demonstrates the talent and infrastructure available in the country for vaccine development.
How has limited government support impacted the development of the Quivax vaccine by the Autonomous University of Querétaro, and what steps has the research team taken to ensure transparency in resource use
Limited government support can have a significant impact on the development of the Quivax vaccine by the Autonomous University of Querétaro. Firstly, limited financial resources provided by the government may hinder the research team’s ability to conduct necessary experiments, acquire vital equipment, or hire skilled researchers, thus leading to delays in the vaccine’s development. Furthermore, limited government support can also result in restricted access to necessary infrastructure and facilities, which might further slow down the research process.
In order to ensure transparency in resource use, the research team has taken several steps. Firstly, they maintain detailed records and documentation of all expenses related to the vaccine development. This includes budgetary allocations, expenditure reports, and invoices. This extensive record-keeping allows for transparency and accountability in the use of limited resources.
Additionally, the research team also engages in regular meetings and consultations with relevant government officials, during which they provide updates on the progress of the vaccine development and discuss their resource needs. By maintaining open communication and actively involving the government in the process, they aim to ensure transparency and avoid any misallocation of resources.
Moreover, the research team has also taken initiatives to seek external funding and collaborations. By partnering with private companies, universities, or international organizations, they can secure additional resources to support their research efforts. These partnerships often involve sharing resources, expertise, and financial support, which contributes to the transparency and accountability of resource use.
Overall, despite limited government support, the research team at the Autonomous University of Querétaro strives to ensure transparency in resource use by maintaining thorough documentation, engaging in regular communication with the government, and seeking external funding and collaborations. These measures not only address resource limitations but also ensure efficient and accountable use of the available resources for the development of the Quivax vaccine.
This breakthrough in vaccine development for pigs against all Covid-19 variants brings us one step closer to safeguarding not just human health, but animal populations as well. A promising development indeed!
1 comment
This breakthrough in vaccine development for pigs against all Covid-19 variants brings us one step closer to safeguarding not just human health, but animal populations as well. A promising development indeed!